Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | KCNT1 | Q5JUK3 | 4/20 | 0.43 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113411 | 1.00 | KMT2A (0.47) | KMT2AMEN1MAPTSTAT3ALDH1A1 | |
| SCHEMBL3299175 | 1.00 | KMT2A (0.47) | KMT2AMEN1MAPTSTAT3ALDH1A1 | |
| SCHEMBL3302704 | 0.90 | ALDH1A1 (0.55) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL3302702 | 0.90 | ALDH1A1 (0.55) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL14113715 | 0.90 | ALDH1A1 (0.55) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL13389879 | 0.88 | KMT2A (0.52) | KMT2AMEN1MAPTSTAT3ALDH1A1 | |
| SCHEMBL3301417 | 0.88 | KMT2A (0.51) | KMT2AMEN1MAPTSTAT3ALDH1A1 | |
| SCHEMBL3301411 | 0.88 | KMT2A (0.51) | KMT2AMEN1MAPTSTAT3ALDH1A1 | |
| SCHEMBL3307431 | 0.83 | ALDH1A1 (0.55) | KMT2AMEN1MAPTALDH1A1GAA | |
| SCHEMBL14113717 | 0.83 | ALDH1A1 (0.55) | KMT2AMEN1MAPTALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | KMT2A 1665/4885MEN1 2505/4885MAPT 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.